Floatz logo

Rebimastat

Lung Cancer

NCIC Clinical Trials GroupSmall moleculePhase 2/3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
65/ 100

Competitive context

304 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

Rebimastat is also rated in:

prostate cancerDormant
B
Indicative ·
62 / 100
View asset →
prostate adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →
hormone-resistant prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →